Hayward, CA-Tuesday, 26 April 2022 [ ايتوس واير ]
(BUSINESS WIRE) – Maui DNA Technologies (“Maui”), a biotechnology company focused on developing innovative biosampling technologies, announces that Prime Discovery has successfully developed Covid Detection. This is a rapid diagnostic test via isothermal amplification to detect the SARS-CoV -2 virus. The sample result can be obtained in less than 30 minutes without the need for RNA extraction and purification. The test uses Maui’s new iSwap Microbiome-EL (No Extraction) sample collection technology that enables RNA extraction from the sample and maintains its stability, protects it against corruption and allows it to be transported and stored at room temperature.
Prime Discovery recently received the CEIVD label to trade in vitro diagnostic medical devices in the European market for its Covid detection device and plans to continue working to obtain 510K approval from the U.S. Food and Drug Administration. The clinical results of Prime Covid Detect were peer-reviewed and recently published in PLOS ONE under the title “A rapid, specific, no-extraction and cost-effective test for isothermal amplification by the reverse transcription loop for SARS detection. CoV – 2 ‘in clinical samples “. It should be noted that the acquisition of the CE mark enables the implementation of a solution in countries in Africa and Asia where rapid and inexpensive diagnosis of various infections with minimal technical expertise and equipment infrastructure is in high demand.
The Prime Covid Detect device utilizes Maui’s unique iSwap Microbiome EL sampling technology with Prime Discovery’s patented isothermal amplification by circular projector technology. This allows isothermal amplification of DNA and thus eliminates the need for expensive thermal cycling equipment required for PCR-based technology. The sample collection protocol without extraction bypasses the expensive and complex step of DNA extraction and purification, saving 60 to 90 minutes of sample processing time for PCR.
Dr. Arun Manoharan, Chief Scientist, Prime Discoveries, commented on the matter: “The COVID-19 outbreak has shown that there is a great need for rapid diagnostic testing. Prime Technologies aims to create a portfolio of solutions that will provide results in less than 45 minutes and requires minimal laboratory requirements, chemical reagents and technical skills.It is ideal for point-of-care testing in rural neighborhoods, mobile testing, border access points and clinical sites with minimal infrastructure.Our work has been demonstrated in ‘ ‘Covid’ pandemic stable performance Maui’s iSwap Microbiome-EL sampling technology for hundreds of clinical samples with performance comparable to or greater than that of reverse transcription polymerase chain reaction (RT-PCR) test solutions Samples remained stable for more than two weeks with minimal acidity RNA as well as high compatibility with isothermal DNA amplification techniques. ” “Our partnership with Maui enables Prime Discovery to develop room temperature sample collection technology without extraction capabilities to enable rapid diagnostic solutions in many areas. These solutions include flu and chlamydia, “he added., Gonorrhea, trichomoniasis, hepatitis, viral hepatitis, human papilloma infection, tuberculosis, herpes virus, syphilis, etc. We are excited to work with Maui for future products that will enable clients to quickly test thousands of patients looking for various types of infections including respiratory and gastrointestinal pathogens, sexually transmitted diseases, and those with antimicrobial resistance. ”
About “Prime Discovery”
Prime Discoveries is developing new, fast diagnostics for emerging pathogen infections with an emphasis on cost-effective, scalable, large-scale and easily automated tests. Founded in 2017 in New York City, Prime Scientists have extensive experience in microbiology, computer biology, laboratory automation, and artificial intelligence from Genentech, Cooper Genomics, and Recompain. Phosphoous and New York University. Prime uses consulting services from leading experts in the field of genomics and public health, including Dr. George Church School and New York University. Prime is also backed by academic institutions, venture capital firms and angel investors, including New York University, Charles Zegar (“Bloomberg”), Esther Dyson (“23andMe”), Box Group and Akron Fusion. Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, François Nader (Moderna, Acceleron, Shire), Unchuckled Ventures and Dobermann Forward, etc. For more information, please visit the following website: www.primediscoveries.com.
About Maui DNA Technologies“
Founded in 2013, Maui DNA Technologies Corporation develops and commercializes iSWAP technology, an innovative biological sample collection system. Maui’s mission is to maintain the integrity of samples from anywhere in the world at room temperature, enabling true diversity of samples across any geographic region or population. At Maui, we’re working to put the future of bio-samples in your hands. For more information, please visit the following link: http://www.mawidna.com.
You can download the original copy of the press release on Business Wire (businesswire.com) at the following link: https://www.businesswire.com/news/home/20220425005323/en/
The original language text of this declaration is the officially approved version. As far as the translation is concerned, it is provided for assistance only, and reference should be made to the original language text, which is the only version with legal consequences.